PharmTech

JULY 28, 2025

Removes Thimerosal from Flu Vaccines Patrick Lavery Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999. Adverse Outcome Pathway Networks as the Basis for the Development of New Approach Methodologies: Liver Toxicity as a Case Study.

Dosage

Pharmacy Times

JUNE 27, 2025

Ross et al published a landmark study in 2016 evaluating psilocybin’s impact on anxiety and depression in 51 patients with life-threatening cancer. It triggered an outflow of new psychedelic research interest and added evidence to the relationship between mystical experience and the efficacy of psilocybin.

Compounding Pharmacies

Pharmacy Times

JULY 8, 2025

SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023. 1 For this retrospective cohort study, the investigators collected data from January 1, 2016, to December 31, 2023, to assess the uptake of biosimilars within the pediatric IBD space. One patient started Inflectra in 2016 and 2017.

HIV Treatment and Prevention Agents

Drug Topics

JUNE 12, 2025

READ MORE: Q&A: Myths, Misinformation Surrounding Hepatitis Vaccines The study cohort included 283 patients 12 years of age or older with an acute HCV Infection who were treatment-naïve. December 19, 2016. Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting Gretchen K. Accessed June 12, 2025.

FDA

The FDA Law Blog

APRIL 7, 2025

Zenrelia comes with serious warnings, including a boxed warning against the use of Zenrelia during vaccination. CVM also objected to the truncation of other information about the timing of vaccines in these promotional materials. Zenrelia promotional materials also included claims about clinical data that the Agency found actionable.

Vaccines

Pharmacy Times

JULY 1, 2025

031), and diagnosis between 2016 and 2018 (OR 1.93, P < 001) as well as 2019 and 2020 (1.88, P < 001). in 2016, representing a period of rapid uptake—and usage was consistently high from 2016 to 2018. 3 The utilization of HER2 therapies increased from 64.6% in 2013 to 80.9%

Compounding Pharmacies

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

Pharmacy Times

JUNE 25, 2025

1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk.

Compounding Pharmacies

pharmaphorum

JUNE 30, 2025

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies

Pharmaceutical Technology

JULY 18, 2025

How will RFK Jr’s American dream for vaccines play out? At BIO, David Ridley, a health economist at Duke University, said based on the reauthorisation experience in 2016, the program is likely to be renewed, but in the meantime, “this is slowing down drug development by a couple of years for many of these drugs.” “I

FDA

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out? J&J gained prostate cancer rights for Zejula from Tesaro in 2016, the latter company was acquired by GSK. Akeega combines the active ingredients in GSK’s PARP inhibitor Zejula (niraparib) and J&J’s androgen blocker Zytiga (abiraterone).

Labelling

STAT

JUNE 24, 2025

She first joined the FDA in 2016 as the director of the office of medical policy at CDER and became the CDER deputy director in 2021. Senate health leader is calling for this week’s meeting of the panel of vaccine advisers handpicked by U.S. Health and Human Services Secretary Robert F. Kennedy Jr.

FDA

pharmaphorum

AUGUST 13, 2025

Skip to main content Wednesday 13 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Pharmaceutical Companies

pharmaphorum

JUNE 19, 2025

Skip to main content Thursday 19 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

pharmaphorum

AUGUST 7, 2025

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Pharmaceutical Companies

pharmaphorum

JUNE 6, 2025

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies

pharmaphorum

JUNE 30, 2025

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

pharmaphorum

JUNE 6, 2025

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies

pharmaphorum

AUGUST 13, 2025

Skip to main content Wednesday 13 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Pharmaceutical Companies

pharmaphorum

AUGUST 13, 2025

Skip to main content Wednesday 13 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Pharmaceutical Companies

pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.

Vaccines

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccines

European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?

Vaccines

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

Vaccines

Pharmaceutical Technology

MAY 22, 2023

The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. CureVac’s lawsuits add to a complex legal landscape for Pfizer/BioNTech that already includes ones from Moderna.

Vaccines

European Pharmaceutical Review

JUNE 29, 2022

As the healthcare sector grows, there is a clear trend towards the expansion of biologic therapeutic drugs and vaccines like the one developed by Novavax. To summarise, bioproduction hurdles include the necessity to be fast, agile and, not to be understated, able to deliver safe and effective vaccines worldwide. _4W2cWlEb439CWlu?startTime=1632749714000

Vaccines

Pharmaceutical Technology

SEPTEMBER 29, 2022

The mRNA-1273.222 vaccine comprises 25µg doses of mRNA-1273 (Spikevax) and a vaccine candidate against the BA.4/BA.5 Moderna has so far obtained authorisations for Omicron-targeting bivalent booster vaccine in the US, Canada, Europe, Australia, South Korea, Switzerland, Japan, Singapore, Taiwan and the UK.

Vaccines

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

pharmaphorum

JUNE 6, 2022

With vaccine hesitancy leading to a rise in measles cases, the FDA’s approval of GlaxoSmithKline’s venerable vaccine Priorix for sale in the US looks timely. The post FDA clears GSK’s Priorix, first new MMR vaccine in 50 years appeared first on. Photo credit: CDC/Dr Heinz F Eichenwald via Wikipedia.

Vaccines

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines

pharmaphorum

OCTOBER 7, 2021

The WHO has given a green light to widespread use of GlaxoSmithKline’s malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The vaccine could soon be available – as an additional malaria control tool – to more children across Africa. link] #VaccinesWork.

Vaccines

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines

pharmaphorum

DECEMBER 14, 2022

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer.

Vaccines

pharmaphorum

JULY 30, 2021

Takeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is spun out into a dedicated company. In 2016, the drugmaker spun out a 25-strong team of UK researchers – focused on neurological and psychiatric disorders – into a new company called Cerevance.

Vaccines